Figure 1.

Adult females from the pivotal studies for adapalene 0.3% gel were analyzed separately for efficacy. Median percent change from baseline for inflammatory, noninflammatory, and total lesion counts from this subgroup are shown. Treatment with adapalene gel, 0.3% produced a greater reduction in all lesion counts compared to vehicle. The overall population of the Phase 3 study included 258 patients and showed similar median lesion reductions to what was seen in the adult female subgroup (e.g., total lesion reduction from Phase 3 was -55.6%).